Business Description
3D Global Biotech Inc
ISIN : TW0006808009
Share Class Description:
ROCO:6808: Ordinary SharesDescription
3D Global Biotech Inc is engaged in developing reconstruction of human tissues and organs and manufactures customized and personalized high-level medical devices.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 35.05 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14 | |||||
| 3-Year EBITDA Growth Rate | -12.4 | |||||
| 3-Year EPS without NRI Growth Rate | -5 | |||||
| 3-Year FCF Growth Rate | -10 | |||||
| 3-Year Book Growth Rate | -14.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.68 | |||||
| 9-Day RSI | 60.92 | |||||
| 14-Day RSI | 57.32 | |||||
| 6-1 Month Momentum % | 68.42 | |||||
| 12-1 Month Momentum % | 13.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.63 | |||||
| Quick Ratio | 6.49 | |||||
| Cash Ratio | 6.27 | |||||
| Days Inventory | 81.02 | |||||
| Days Sales Outstanding | 36.67 | |||||
| Days Payable | 53.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | -0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 25.56 | |||||
| Operating Margin % | -304.62 | |||||
| Net Margin % | -280.87 | |||||
| FCF Margin % | -156.99 | |||||
| ROE % | -18.37 | |||||
| ROA % | -16.77 | |||||
| ROIC % | -38.28 | |||||
| ROC (Joel Greenblatt) % | -344.41 | |||||
| ROCE % | -18.19 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 92.26 | |||||
| PB Ratio | 6.57 | |||||
| Price-to-Tangible-Book | 10.07 | |||||
| EV-to-EBIT | -28.88 | |||||
| EV-to-EBITDA | -47.33 | |||||
| EV-to-Revenue | 82.23 | |||||
| EV-to-FCF | -52.38 | |||||
| Price-to-Net-Current-Asset-Value | 13.31 | |||||
| Price-to-Net-Cash | 14.26 | |||||
| Earnings Yield (Greenblatt) % | -3.46 | |||||
| FCF Yield % | -1.75 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers